JAK3 and experimental autoimmune encephalomyelitis: Furthermore, the selective JAK3 inhibitor PF-06651600 demonstrated in vivo treatment efficacy in rodent models of adjuvant-induced arthritis and experimental autoimmune encephalomyelitis (21), 2 T cell–mediated inflammatory disorders.